Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PureTech Health plc

< Previous 1 2 3 4 Next >
PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Participation in Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From PureTech Health plc
Via Business Wire
Tickers KRTX PRTC ZLAB
PureTech Announces Participation at the Jefferies London Healthcare Conference
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Health plc – Half-Year Report
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
From PureTech Health plc
Via Business Wire
Tickers PRTC
PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
From PureTech Health plc
Via Business Wire
Tickers PRTC
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.